PressFebruary 12, 2025 Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
PressFebruary 12, 2025 Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
PressFebruary 7, 2025 Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
PressFebruary 7, 2025 Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare’s USD $170K Equity Investment
PressFebruary 7, 2025 Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
PressJanuary 31, 2025 MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
PressJanuary 31, 2025 Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
PressJanuary 31, 2025 Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
PressJanuary 31, 2025 HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
PressJanuary 31, 2025 Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
PressJanuary 28, 2025 Mindbio Announces Successful Outcome of Mandatory Independent Safety Audit in Phase 2b Clinical Trials
PressJanuary 28, 2025 atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
PressJanuary 24, 2025 Red Light Holland Appoints Keith Li as Chief Financial Officer and Provides Corporate Updates
PressJanuary 24, 2025 Filament Health Announces Shipment Of Botanical Psilocybin To The University of Wisconsin-Madison
PressJanuary 24, 2025 Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine Addiction
PressJanuary 24, 2025 Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
PressJanuary 20, 2025 PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
PressJanuary 17, 2025 Mindbio Provides Update on Multiple Phase 2B Clinical Trials and Technological Developments
PressJanuary 17, 2025 Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
